Abstract
Background: Heavily treated patients with non-small cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated. Progression-free (PFS) and overall (OS) survival were monitored. Results: Median follow-up was 13.2 months. Twenty-three patients had received three or more prior therapy lines. Overall response rate was 32% [95% confidence interval (CI)=22%-39%] and 26% of patients achieved stable disease. Median PFS was 4.4 (95% CI=2.8-8.3) months and median OS 18.0 (95% CI=16.2-30.7) months. Nine patients harboring EGFR mutations had a long-lasting partial response. A shorter OS was found in patients with a higher TIMP1 expression (p=0.006). Conclusion: Irinotecan combined with bevacizumab had favorable antitumor activity in heavily pretreated patients with NSCLC. These results suggest this is a reasonable strategy, particularly for patients with low TIMP1 expression.
Footnotes
↵* These Authors contributed equally to this study.
This article is freely accessible online.
Disclaimer
Preliminary results from this study were previously shared during the 2014 LALCA Meeting (August 21-23, 2014 Lima, Peru) and the 16th World Conference on Lung Cancer (September 4-9, 2015 Denver, Colorado, USA - Abstract 2521).
Funding
This work was supported by the Foundation for Clinical and Applied Cancer Research-FICMAC (Bogotá, Colombia) research grant 020-2014.
Conflict of Interest
The Authors declare they have no competing conflict of interest to declare.
- Received June 14, 2017.
- Revision received July 13, 2017.
- Accepted July 17, 2017.
- Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved